Literature DB >> 28957949

Ovarian Cancer Prevention in High-risk Women.

Sarah M Temkin1, Jennifer Bergstrom, Goli Samimi, Lori Minasian.   

Abstract

Ovarian carcinoma is the most lethal malignancy of the female genital tract. Population-based trials in the general population have not demonstrated that screening improves early detection or survival. Therefore, application of prevention strategies is vital to improving outcomes from this disease. Surgical prevention reduces risk and prophylactic risk-reducing salpingo-oophorectomy is the most effective means to prevent ovarian carcinoma in the high-risk patient although the risks do not outweigh the benefits in average risk patients. Other surgical and medical options have unknown or limited efficacy in the high-risk patient. In this review, we define the patient at high risk for ovarian cancer, discuss how to identify these women and weigh their available ovarian cancer prevention strategies.

Entities:  

Mesh:

Year:  2017        PMID: 28957949      PMCID: PMC5920567          DOI: 10.1097/GRF.0000000000000318

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  134 in total

1.  Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.

Authors:  Antonis C Antoniou; Matti Rookus; Nadine Andrieu; Richard Brohet; Jenny Chang-Claude; Susan Peock; Margaret Cook; D Gareth Evans; Rosalind Eeles; Catherine Nogues; Laurence Faivre; Paul Gesta; Flora E van Leeuwen; Margreet G E M Ausems; Ana Osorio; Trinidad Caldes; Jacques Simard; Jan Lubinski; Anne-Marie Gerdes; Edith Olah; Christine Fürhauser; Hakan Olsson; Brita Arver; Paolo Radice; Douglas F Easton; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

2.  The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.

Authors:  Michael Herman Chui; Paul Ryan; Jordan Radigan; Sarah E Ferguson; Aaron Pollett; Melyssa Aronson; Kara Semotiuk; Spring Holter; Keiyan Sy; Janice S Kwon; Anita Soma; Naveena Singh; Steven Gallinger; Patricia Shaw; Jocelyne Arseneau; William D Foulkes; C Blake Gilks; Blaise A Clarke
Journal:  Am J Surg Pathol       Date:  2014-09       Impact factor: 6.394

3.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

4.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

5.  Low-dose aspirin use and the risk of ovarian cancer in Denmark.

Authors:  L Baandrup; S K Kjaer; J H Olsen; C Dehlendorff; S Friis
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

6.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Authors:  Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

7.  Effect of fenretinide on ovarian carcinoma occurrence.

Authors:  Giuseppe De Palo; Luigi Mariani; Tiziana Camerini; Ettore Marubini; Franca Formelli; Barbara Pasini; Andrea Decensi; Umberto Veronesi
Journal:  Gynecol Oncol       Date:  2002-07       Impact factor: 5.482

8.  Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.

Authors:  A Benshushan; N Rojansky; M Chaviv; S Arbel-Alon; A Benmeir; T Imbar; A Brzezinski
Journal:  Climacteric       Date:  2009-10       Impact factor: 3.005

9.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

Review 10.  Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.

Authors:  Anliang Dong; Yan Lu; Bingjian Lu
Journal:  J Cancer       Date:  2016-07-05       Impact factor: 4.207

View more
  11 in total

1.  A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.

Authors:  Vera Loizzi; Ettore Cicinelli; Vittoria Del Vecchio; Francesca Arezzo; Xheni Deromemaj; Anila Kardhashi; Angelo Paradiso; Francesco Legge; Maria Iole Natalicchio; Leonardo Resta; Nicoletta Resta; Daria Carmela Loconte; Gennaro Cormio
Journal:  Acta Biomed       Date:  2022-08-31

Review 2.  New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review).

Authors:  Raluca Ana-Maria Mogos; Razvan Popovici; Adina Elena Tanase; Tudor Calistru; Paula Popovici; Mihaela Grigore; Alexandru Carauleanu
Journal:  Exp Ther Med       Date:  2022-05-04       Impact factor: 2.751

Review 3.  PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies.

Authors:  Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

4.  Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.

Authors:  James Yarmolinsky; Caroline J Bull; Emma E Vincent; Jamie Robinson; Axel Walther; George Davey Smith; Sarah J Lewis; Caroline L Relton; Richard M Martin
Journal:  JAMA       Date:  2020-02-18       Impact factor: 56.272

Review 5.  Nutrition in Gynecological Diseases: Current Perspectives.

Authors:  Michał Ciebiera; Sahar Esfandyari; Hiba Siblini; Lillian Prince; Hoda Elkafas; Cezary Wojtyła; Ayman Al-Hendy; Mohamed Ali
Journal:  Nutrients       Date:  2021-04-02       Impact factor: 5.717

6.  Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.

Authors:  Anna Maria Annoni; Claudia Longhini
Journal:  PLoS One       Date:  2022-03-18       Impact factor: 3.240

7.  Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas.

Authors:  Suparna Mazumder; Valerie Swank; Nina Dvorina; Justin M Johnson; Vincent K Tuohy
Journal:  Clin Exp Vaccine Res       Date:  2022-05-31

Review 8.  Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.

Authors:  Madison Pereira; Kathy Matuszewska; Alice Glogova; Jim Petrik
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

9.  Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.

Authors:  D Sangiolo; G Valabrega; S Capellero; J Erriquez; C Melano; G Mesiano; S Genta; A Pisacane; G Mittica; E Ghisoni; M Olivero; M F Di Renzo; M Aglietta
Journal:  Sci Rep       Date:  2020-04-15       Impact factor: 4.379

10.  Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians.

Authors:  Goli Samimi; Brandy M Heckman-Stoddard; Christine Holmberg; Bethany Tennant; Bonny Bloodgood Sheppard; Kisha I Coa; Shelley S Kay; Leslie G Ford; Eva Szabo; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.